Alkem Labs to Acquire 51-55% Stake in Occlutech Holding AG for EUR 180.70 Million
Alkem Medtech Private Limited will acquire 51-55% of Occlutech Holding AG for EUR 180.70 million cash. Occlutech develops cardiac implants. The deal is expected to close by June 30, 2026. This acquisition marks Alkem's entry into the cardiovascular devices segment.
The acquisition is significant as it marks entry into a new business vertical and involves a substantial investment, but it is conducted through a subsidiary and its financial impact on the parent company is yet to be fully realized.
The acquisition represents a strategic expansion into a new business segment (advanced cardiovascular devices) for Alkem Laboratories, which is generally viewed positively.
Alkem Laboratories Limited, through its wholly-owned subsidiary Alkem Medtech Private Limited, has entered into a Binding Offer to acquire a minimum of 51% and up to 55% of the total issued equity share capital of Occlutech Holding AG for a cash consideration. The total equity value for Occlutech is estimated at EUR 180.70 million.
Occlutech, a Swiss company incorporated in 2000, specializes in the development, manufacturing, and marketing of minimally invasive cardiac implants for congenital heart defects, stroke prevention, and heart failure. The company has a global presence with revenues generated from Germany, France, Italy, the UK, Spain, Japan, and recently entered the United States. For the period January-December 2024, Occlutech reported a turnover of EUR 43.95 million (INR 397.80 crore) and a net loss of EUR 20.52 million (Loss INR 185.73 crore). Estimated turnover for January-December 2025 is EUR 49.38 million (INR 487.87 crore) with an estimated loss of EUR 6.85 million (Loss INR 67.65 crore).
This proposed acquisition marks Alkem's entry into the advanced cardiovascular devices business segment. The transaction is expected to be completed on or before June 30, 2026, subject to customary closing conditions, including foreign direct investment clearances in Italy and Sweden, and a precautionary filing in France.
The Proposed Acquisition does not constitute a related party transaction, and none of Alkem's promoters, promoter group, or group companies have any interest in Occlutech. The acquisition is being undertaken at arms-length.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.